Hims & Hers Health (NYSE:HIMS) Stock Price Down 5.4% – Time to Sell?

Hims & Hers Health, Inc. (NYSE:HIMS)’s stock price was down 5.4% on Friday . The stock traded as low as $54.24 and last traded at $54.74. Approximately 17,406,204 shares traded hands during trading, a decline of 47% from the average daily volume of 32,648,639 shares. The stock had previously closed at $57.87.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on the company. Wall Street Zen downgraded Hims & Hers Health from a “buy” rating to a “hold” rating in a report on Monday, July 28th. Citigroup restated a “sell” rating on shares of Hims & Hers Health in a report on Monday, June 23rd. UBS Group set a $30.00 price objective on Hims & Hers Health in a report on Monday, June 23rd. Canaccord Genuity Group restated a “buy” rating and issued a $68.00 price objective on shares of Hims & Hers Health in a report on Friday, September 12th. Finally, Truist Financial decreased their price objective on Hims & Hers Health from $48.00 to $37.00 and set a “hold” rating for the company in a report on Monday, August 18th. Two analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and three have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Reduce” and a consensus price target of $38.92.

Hims & Hers Health Price Performance

The firm has a market capitalization of $11.89 billion, a P/E ratio of 65.77, a P/E/G ratio of 3.55 and a beta of 2.25. The company has a debt-to-equity ratio of 1.72, a current ratio of 4.98 and a quick ratio of 4.46. The stock’s fifty day simple moving average is $51.47 and its 200 day simple moving average is $47.25.

Hims & Hers Health (NYSE:HIMS) last announced its earnings results on Monday, August 4th. The company reported $0.17 EPS for the quarter, missing analysts’ consensus estimates of $0.18 by ($0.01). The firm had revenue of $544.83 million during the quarter, compared to the consensus estimate of $550.06 million. Hims & Hers Health had a return on equity of 26.26% and a net margin of 9.63%.The business’s revenue for the quarter was up 72.6% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.06 earnings per share. Hims & Hers Health has set its Q3 2025 guidance at EPS. FY 2025 guidance at EPS. On average, equities research analysts predict that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

Insiders Place Their Bets

In other Hims & Hers Health news, CFO Oluyemi Okupe sold 145,000 shares of the business’s stock in a transaction dated Monday, September 15th. The shares were sold at an average price of $55.35, for a total value of $8,025,750.00. Following the completion of the transaction, the chief financial officer directly owned 128,984 shares in the company, valued at approximately $7,139,264.40. The trade was a 52.92% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Patrick Harrison Carroll sold 60,000 shares of the business’s stock in a transaction dated Wednesday, August 6th. The stock was sold at an average price of $53.58, for a total transaction of $3,214,800.00. Following the completion of the transaction, the insider owned 169,940 shares of the company’s stock, valued at $9,105,385.20. This represents a 26.09% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 1,622,727 shares of company stock worth $83,566,691. 13.71% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Hims & Hers Health

A number of large investors have recently modified their holdings of HIMS. Invesco Ltd. grew its stake in shares of Hims & Hers Health by 502.2% during the second quarter. Invesco Ltd. now owns 2,552,405 shares of the company’s stock worth $127,237,000 after acquiring an additional 2,128,587 shares during the last quarter. Nuveen LLC purchased a new stake in shares of Hims & Hers Health during the first quarter worth about $58,403,000. Clear Street LLC purchased a new stake in shares of Hims & Hers Health during the second quarter worth about $83,582,000. Norges Bank purchased a new stake in shares of Hims & Hers Health during the second quarter worth about $78,464,000. Finally, Marex Group plc purchased a new stake in shares of Hims & Hers Health during the second quarter worth about $53,626,000. Hedge funds and other institutional investors own 63.52% of the company’s stock.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.